ArticleThe British journal of ophthalmology2022

Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.

Rashmi Deshmukh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.